Quick Answer
CNS Pharmaceuticals, Inc. reported Diluted EPS of $35.75 per share (loss) for fiscal year 2025.
CNS Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$35.75 | +92.3% |
| 2024 | -$466.89 | +96.3% |
| 2023 | -$12509.11 | -111389.4% |
| 2022 | -$11.22 | +32.0% |
| 2021 | -$16.50 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.76 | +96.2% | +10.3% |
| June 30, 2025 | -$6.42 | +99.8% | -306.3% |
| March 31, 2025 | -$1.58 | +99.8% | +99.0% |
| September 30, 2024 | -$153.20 | -183.0% | +96.2% |
| June 30, 2024 | -$4049.20 | -7707.9% | -296.8% |
| March 31, 2024 | -$1020.48 | -39300.8% | -1784.9% |
| September 30, 2023 | -$54.14 | -2014.8% | -4.4% |
| June 30, 2023 | -$51.86 | -1842.3% | -1902.3% |
- CNS Pharmaceuticals, Inc. showed an increase of +92.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, CNS Pharmaceuticals, Inc.’s diluted eps has declined by 116.7% (from $16.50 per share (loss) to $35.75 per share (loss)).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: